Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Aust, Stefanie ^a   Bachmayr Heyda, Anna ^a   Pateisky, Petra ^a   Tong, Dan ^a   Darb Esfahani, Silvia ^b   Denkert, Carsten ^b   Chekerov, Radoslav ^b   Sehouli, Jalid ^b   Mahner, Sven ^c   Van Gorp, Toon ^d,e   Vergote, Ignace ^d   Speiser, Paul ^a   Horvat, Reinhard ^a   Zeillinger, Robert ^a   Pils, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Estrogen receptor; Immunohistochemistry; Ovarian cancer; Prognosis; TRAP1

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TISSUE MICROARRAY; TREATMENT RESPONSE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866149982     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-69     Document Type: Article

References (30)

1. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 2010, 176:393-401. 10.2353/ajpath.2010.090521, 2797899, 19948822.
2. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F, Landriscina M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett 2009, 279:39-46. 10.1016/j.canlet.2009.01.018, 19217207.
3. Calderwood SK. Heat shock proteins in breast cancer progression-a suitable case for treatment?. Int J Hyperthermia 2010, 26:681-685. 10.3109/02656736.2010.490254, 3123897, 20653417.
4. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol 2010, 117:177-182. 10.1016/j.ygyno.2009.10.078, 19942270.
5. Cohen M, Dromard M, Petignat P. Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol 2010, 119:164-166. 10.1016/j.ygyno.2010.05.027, 20580418.
6. Langmar Z, Vlesko G. The potential role of heat shock proteins in the treatment of ovarian cancer. Orv Hetil 2011, 152:92-95. 10.1556/OH.2011.29024, 21205608.
7. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003, 1:66. 10.1186/1477-7827-1-66, 270001, 14609433.
8. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001, 168:173-181. 10.1016/S0304-3835(01)00532-8, 11403922.
9. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005, 12:851-866. 10.1677/erc.1.01039, 16322326.
10. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 2007, 106:461-468. 10.1016/j.ygyno.2007.05.009, 17624412.
11. Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR. Molecular clustering based on ERalpha and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol 2011, 24:453-462. 10.1038/modpathol.2010.211, 3058634, 21102415.
12. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H, Surowiak P. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011, 17:511-518. 10.1007/s12253-010-9340-0, 3158974, 21207255.
13. Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N, Friese K, Mylonas I. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010, 281:511-517. 10.1007/s00404-009-1185-y, 19639330.
14. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007, 18:1051-1059.
15. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005, 96:671-677. 10.1016/j.ygyno.2004.11.010, 15721410.
16. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 2009, 19:620-627. 10.1111/IGC.0b013e3181a44b62, 19509560.
17. Yang XY, Xi MR, Yang KX, Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol 2009, 113:99-104. 10.1016/j.ygyno.2008.12.018, 19178934.
18. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000, 89:1783-1791. 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D, 11042574.
19. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270. 10.1016/j.cell.2007.08.028, 17956728.
20. Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, Landriscina M, Esposito F. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 2007, 10:342-350. 10.1080/10253890701314863, 17853063.
21. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005, 23:7911-7918. 10.1200/JCO.2005.02.9363, 16204010.
22. Iba T, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Simada M, Uegaki K, Naniwa J, Terakawa N. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 2004, 95:418-423. 10.1111/j.1349-7006.2004.tb03225.x, 15132769.
23. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009, 28:586-604. 10.1002/sim.3495, 19051220.
24. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003, 1:73. 10.1186/1477-7827-1-73, 239900, 14577831.
25. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009, 114:480-485. 10.1016/j.ygyno.2009.05.045, 2756056, 19560192.
26. Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS. Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2009, 18:1624-1630. 10.1158/1055-9965.EPI-08-1214, 2814542, 19383883.
27. Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 2009, 115:401-406. 10.1016/j.ygyno.2009.08.023, 19796795.
28. Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F, Piscazzi A, Paladino S, Sarnataro D, Garbi C, et al. TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ 2011, 19:592-604.
29. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000, 275:3305-3312. 10.1074/jbc.275.5.3305, 10652318.
30. Liu D, Hu J, Agorreta J, Cesario A, Zhang Y, Harris AL, Gatter K, Pezzella F. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett 2010, 296:194-205. 10.1016/j.canlet.2010.04.017, 20471161.